BACKGROUND: To study the 1-year evolution of quantitative dual-task gait parameters in comparison with single-task gait parameters and detailed neuropsychological assessment in patients with multiple sclerosis (MS) treated with natalizumab. METHODS: Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured and assessed twice at the 1-year interval in 9 consecutive patients with MS treated with natalizumab. RESULTS: Dual-task-related gait changes (walking speed, stride length and stride time while performing semantic fluency and walking speed, and stride time while performing phonemic fluency) showed a significant improvement after 1 year of treatment with natalizumab. The single walking task and detailed neuropsychological assessment did not present any modification. CONCLUSIONS: Dual-task-related gait changes using a cognitive task with a specific executive demand represent an interesting marker of disease-modifying therapy in patients with MS.
BACKGROUND: To study the 1-year evolution of quantitative dual-task gait parameters in comparison with single-task gait parameters and detailed neuropsychological assessment in patients with multiple sclerosis (MS) treated with natalizumab. METHODS: Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured and assessed twice at the 1-year interval in 9 consecutive patients with MS treated with natalizumab. RESULTS: Dual-task-related gait changes (walking speed, stride length and stride time while performing semantic fluency and walking speed, and stride time while performing phonemic fluency) showed a significant improvement after 1 year of treatment with natalizumab. The single walking task and detailed neuropsychological assessment did not present any modification. CONCLUSIONS: Dual-task-related gait changes using a cognitive task with a specific executive demand represent an interesting marker of disease-modifying therapy in patients with MS.
Authors: A Perrochon; R Holtzer; M Laidet; S Armand; F Assal; P H Lalive; G Allali Journal: J Neural Transm (Vienna) Date: 2016-12-22 Impact factor: 3.575
Authors: Pierfilippo De Sanctis; Brenda R Malcolm; Peter C Mabie; Ana A Francisco; Wenzhu B Mowrey; Sonja Joshi; Sophie Molholm; John J Foxe Journal: Clin Neurophysiol Date: 2020-02-21 Impact factor: 3.708